Taking High-Tech to the Field: Leukemia Diagnosis in Pediatric Mexican Patients from Vulnerable and Remote Regions

Background/Objectives: Acute leukemia, the most common childhood cancer, poses a significant public health challenge in low- and middle-income countries (LMICs) due to its high incidence and mortality rates. Survival rates in these regions are often lower, primarily due to delayed and inaccurate diagnoses, limited access to treatment, therapy abandonment, therapy-related toxicity, and inadequate healthcare infrastructure. In Mexico, a new initiative called OncoCREAN has been developed to address this urgent need by establishing local treatment centers near pediatric patients' home cities, ensuring timely cancer detection and comprehensive disease treatment. Methods: A retrospective observational study was conducted on pediatric patients treated at the Mexican Social Security Institute (IMSS) between 18 May 2022 and 30 June 2025. Patients presenting clinical suspicion of acute leukemia were referred to OncoCREAN centers for sample collection and subsequent shipment to the Oncoimmunology and Cytomics Laboratory (OCL), where immunophenotyping confirmed the diagnoses. Results: The implementation of the OncoCREAN model significantly reduced diagnostic turnaround times, facilitating timely therapeutic decisions, minimized uncertainty, and optimized clinical management. The decentralized framework demonstrated feasibility across diverse geographic regions, ensuring access to advanced diagnostic technology for vulnerable populations and generating valuable data on disease incidence and molecular profiles. Conclusions: The OncoCREAN model highlights the critical importance of decentralizing high-technology diagnostic resources in modern pediatric oncology. This new approach to translational research that is accessible, inclusive, and relevant to society creates a paradigm shift in the management of childhood cancer and other diseases.